First-in-Class ROR1 Small Molecule Inhibitor (KAN0439834) Downregulated Wnt-Canonical and Non-Canonical Signaling Pathways and Induced Apoptosis of CLL Cells
Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Håkan Mellstedt(Karolinska University Hospital), Thomas Olin(Kancera (Sweden)), Ali Moshfegh(Karolinska University Hospital), Charlotta Löfberg(Kancera (Sweden)), Anders Österborg(Karolinska University Hospital), Amir Hossein Daneshmanesh(Karolinska University Hospital), Jan Vågberg(Kancera (Sweden)), Elisabeth Olsson(Karolinska Institutet), Byström Styrbjörn(Karolinska Institutet), Johan Schultz(Kancera (Sweden)), Martin Norin(Kancera (Sweden)), Carina Norström(Kancera (Sweden))
Cited by 6
Related Papers
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
|Journal of Clinical Oncology|1998|258
Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
|International Journal of Molecular Sciences|2014|202